Browsing by Author "Kearney, Mary F."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    HIV evolution and diversity in ART-treated patients
    (BioMed Central, 2018-01-30) Van Zyl, Gert; Bale, Michael J.; Kearney, Mary F.
    Characterizing HIV genetic diversity and evolution during antiretroviral therapy (ART) provides insights into the mechanisms that maintain the viral reservoir during ART. This review describes common methods used to obtain and analyze intra-patient HIV sequence data, the accumulation of diversity prior to ART and how it is affected by suppressive ART, the debate on viral replication and evolution in the presence of ART, HIV compartmentalization across various tissues, and mechanisms for the emergence of drug resistance. It also describes how CD4+ T cells that were likely infected with latent proviruses prior to initiating treatment can proliferate before and during ART, providing a renewable source of infected cells despite therapy. Some expanded cell clones carry intact and replication-competent proviruses with a small fraction of the clonal siblings being transcriptionally active and a source for residual viremia on ART. Such cells may also be the source for viral rebound after interrupting ART. The identical viral sequences observed for many years in both the plasma and infected cells of patients on long-term ART are likely due to the proliferation of infected cells both prior to and during treatment. Studies on HIV diversity may reveal targets that can be exploited in efforts to eradicate or control the infection without ART.
  • Thumbnail Image
    Item
    No evidence of HIV replication in children on antiretroviral therapy
    (American Society for Clinical Investigation, 2017-04) Van Zyl, Gert U.; Katusiime, Mary Grace; Wiegand, Ann; McManus, William R.; Bale, Michael J.; Halvas, Elias K.; Luke, Brian; Boltz, Valerie F.; Spindler, Jonathan; Laughton, Barbara; Engelbrecht, Susan; Coffin, John M.; Cotton, Mark F.; Shao, Wei; Mellors, John W.; Kearney, Mary F.
    ENGLISH ABSTRACT: It remains controversial whether current antiretroviral therapy (ART) fully suppresses the cycles of HIV replication and viral evolution in vivo. If replication persists in sanctuary sites such as the lymph nodes, a high priority should be placed on improving ART regimes to target these sites. To investigate the question of ongoing viral replication on current ART regimens, we analyzed HIV populations in longitudinal samples from 10 HIV-1–infected children who initiated ART when viral diversity was low. Eight children started ART at less than ten months of age and showed suppression of plasma viremia for seven to nine years. Two children had uncontrolled viremia for fifteen and thirty months, respectively, before viremia suppression, and served as positive controls for HIV replication and evolution. These latter 2 children showed clear evidence of virus evolution, whereas multiple methods of analysis bore no evidence of virus evolution in any of the 8 children with viremia suppression on ART. Phylogenetic trees simulated with the recently reported evolutionary rate of HIV-1 on ART of 6 × 10⁻⁴ substitutions/site/month bore no resemblance to the observed data. Taken together, these data refute the concept that ongoing HIV replication is common with ART and is the major barrier to curing HIV-1 infection.